Engineered affinity proteins--generation and applications.

The use of combinatorial protein engineering to design proteins with novel binding specificities and desired properties has evolved into a powerful technology, resulting in the recent advances in protein library selection strategies and the emerge of a variety of new engineered affinity proteins. The need for different protein library selection methods is due to that each target protein pose different challenges in terms of its availability and inherent properties. At present, alternative engineered affinity proteins are starting to complement and even challenge the classical immunoglobulins in different applications in biotechnology and potentially also for in vivo use as imaging agents or as biotherapeutics. This review article covers the generation and use of affinity proteins generated through combinatorial protein engineering. The most commonly used selection techniques for isolation of desired variants from large protein libraries are described. Different antibody derivatives, as well as a variety of the most validated engineered protein scaffolds, are discussed. In addition, we provide an overview of some of the major present and future applications for these engineered affinity proteins in biotechnology and medicine.

[1]  A. Lim,et al.  Directed evolution of high-affinity antibody mimics using mRNA display. , 2002, Chemistry & biology.

[2]  J. Deisenhofer Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. , 1981, Biochemistry.

[3]  V. Tolmachev,et al.  Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors. , 2007, International journal of molecular medicine.

[4]  Patrick Amstutz,et al.  CD4-Specific Designed Ankyrin Repeat Proteins Are Novel Potent HIV Entry Inhibitors with Unique Characteristics , 2008, PLoS pathogens.

[5]  Anthony Williams,et al.  DX-88 and HAE: a developmental perspective. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[6]  B. Groner,et al.  Peptide aptamers: recent developments for cancer therapy , 2005, Expert opinion on biological therapy.

[7]  Eric T. Boder,et al.  Yeast surface display for screening combinatorial polypeptide libraries , 1997, Nature Biotechnology.

[8]  Arne Skerra,et al.  Anticalins as an alternative to antibody technology , 2005, Expert opinion on biological therapy.

[9]  G. Magnusson,et al.  Use of bacteriophage T7 displayed peptides for determination of monoclonal antibody specificity and biosensor analysis of the binding reaction. , 1999, Analytical biochemistry.

[10]  P. Parren,et al.  Immunogenicity screening in protein drug development , 2007, Expert opinion on biological therapy.

[11]  H. Brismar,et al.  Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. , 2007, Protein engineering, design & selection : PEDS.

[12]  L. Black,et al.  Phage T4 SOC and HOC display of biologically active, full-length proteins on the viral capsid. , 1998, Gene.

[13]  K. D. Hardman,et al.  Single-chain antigen-binding proteins. , 1988, Science.

[14]  A. Skerra,et al.  Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Mathias Uhlén,et al.  Microbead display of proteins by cell-free expression of anchored DNA. , 2003, Journal of biotechnology.

[16]  J. Scott,et al.  Searching for peptide ligands with an epitope library. , 1990, Science.

[17]  Vladimir Tolmachev,et al.  Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. , 2007, Cancer research.

[18]  B. Moza,et al.  Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists , 2007, Nature Medicine.

[19]  Jakob Dogan,et al.  Structural basis for molecular recognition in an affibody:affibody complex. , 2006, Journal of molecular biology.

[20]  Andreas Plückthun,et al.  Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. , 2007, Structure.

[21]  M. Snyder,et al.  Analyzing antibody specificity with whole proteome microarrays , 2003, Nature Biotechnology.

[22]  Arne Skerra,et al.  Alternative binding proteins: Anticalins – harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities , 2008, The FEBS journal.

[23]  Andreas Plückthun,et al.  Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. , 2003, Journal of molecular biology.

[24]  David W. Colby,et al.  Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Koide,et al.  Probing protein conformational changes in living cells by using designer binding proteins: Application to the estrogen receptor , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Gambhir,et al.  Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. , 2004, Protein engineering, design & selection : PEDS.

[27]  M. A. Carrondo,et al.  Structure of wild-type Plk-1 kinase domain in complex with a selective DARPin. , 2008, Acta crystallographica. Section D, Biological crystallography.

[28]  Andreas Plückthun,et al.  Intracellular Kinase Inhibitors Selected from Combinatorial Libraries of Designed Ankyrin Repeat Proteins* , 2005, Journal of Biological Chemistry.

[29]  S. Ståhl,et al.  Selection and characterization of an HIV‐1 gp120‐binding affibody ligand , 2006, Biotechnology and applied biochemistry.

[30]  L. Jendeberg,et al.  Kinetic analysis of the interaction between protein a domain variants and human Fc using plasmon resonance detection , 1995, Journal of molecular recognition : JMR.

[31]  David E. Golan,et al.  Protein therapeutics: a summary and pharmacological classification , 2008, Nature Reviews Drug Discovery.

[32]  H. Steven Wiley,et al.  Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library , 2003, Nature Biotechnology.

[33]  G. Adams,et al.  In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. , 2005, Cancer biotherapy & radiopharmaceuticals.

[34]  C. Vanhove,et al.  SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression , 2008, Molecular Imaging and Biology.

[35]  A. Plückthun,et al.  Isolation of Intracellular Proteinase Inhibitors Derived from Designed Ankyrin Repeat Proteins by Genetic Screening* , 2006, Journal of Biological Chemistry.

[36]  M. Scholle,et al.  Molecular recognition properties of FN3 monobodies that bind the Src SH3 domain. , 2004, Chemistry & biology.

[37]  M. Uhlén,et al.  Staphylococcal protein A consists of five IgG-binding domains. , 1986, European journal of biochemistry.

[38]  Jodi R Parrish,et al.  Yeast two-hybrid contributions to interactome mapping. , 2006, Current opinion in biotechnology.

[39]  Y Husimi,et al.  In vitro virus: Bonding of mRNA bearing puromycin at the 3′‐terminal end to the C‐terminal end of its encoded protein on the ribosome in vitro , 1997, FEBS letters.

[40]  A. Bruskin,et al.  Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[41]  S. Hober,et al.  Development of affinity columns for the removal of high‐abundance proteins in cerebrospinal fluid , 2009 .

[42]  G. P. Smith,et al.  Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. , 1988, Gene.

[43]  M. Uhlén,et al.  Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A. , 2001, European journal of biochemistry.

[44]  M. Uhlén,et al.  A synthetic IgG-binding domain based on staphylococcal protein A. , 1987, Protein engineering.

[45]  N. Damle,et al.  Biopharmaceutical drug discovery using novel protein scaffolds. , 2006, Current opinion in biotechnology.

[46]  David E. Gloriam,et al.  ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome , 2007, Nature Methods.

[47]  A. Bradbury,et al.  Antibodies from phage antibody libraries. , 2004, Journal of immunological methods.

[48]  S. Brenner,et al.  Surface Display of Proteins on Bacteriophage λ Heads , 1996 .

[49]  M. Uhlén,et al.  Anti‐idiotypic protein domains selected from protein A‐based affibody libraries , 2002, Proteins.

[50]  M. Dennis,et al.  Kunitz domain inhibitors of tissue factor-factor VIIa. I. Potent inhibitors selected from libraries by phage display. , 1994, The Journal of biological chemistry.

[51]  A. Karlström,et al.  Dual labeling of a binding protein allows for specific fluorescence detection of native protein. , 2001, Analytical biochemistry.

[52]  Dan S. Tawfik,et al.  Microbead display by in vitro compartmentalisation: selection for binding using flow cytometry , 2002, FEBS letters.

[53]  P. Hudson,et al.  Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.

[54]  P. Nordlund,et al.  Structural basis for recognition by an in vitro evolved affibody , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[55]  D. Coomber,et al.  CIS display: In vitro selection of peptides from libraries of protein-DNA complexes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[56]  H R Hoogenboom,et al.  Natural and designer binding sites made by phage display technology. , 2000, Immunology today.

[57]  P. Carter Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.

[58]  S. Ståhl,et al.  Generation of Affibody® ligands binding interleukin‐2 receptor α/CD25 , 2008, Biotechnology and applied biochemistry.

[59]  E. Lundberg,et al.  Selection and characterization of Affibody® ligands to the transcription factor c‐Jun , 2009, Biotechnology and applied biochemistry.

[60]  Z. Xu,et al.  Inhibition of the CD28-CD80 co-stimulation signal by a CD28-binding affibody ligand developed by combinatorial protein engineering. , 2003, Protein engineering.

[61]  H. Wernérus,et al.  Evaluation of Staphylococcal Cell Surface Display and Flow Cytometry for Postselectional Characterization of Affinity Proteins in Combinatorial Protein Engineering Applications , 2007, Applied and Environmental Microbiology.

[62]  C. Hovens,et al.  Mutagenesis and selection of PDZ domains that bind new protein targets , 1999, Nature Biotechnology.

[63]  A. Plückthun,et al.  Directed in Vitro Evolution and Crystallographic Analysis of a Peptide-binding Single Chain Antibody Fragment (scFv) with Low Picomolar Affinity* , 2004, Journal of Biological Chemistry.

[64]  A. Karlström,et al.  Fluorescence resonance energy transfer-based detection of analytes using antiidiotypic affinity protein pairs. , 2004, Analytical biochemistry.

[65]  R. Bruccoleri,et al.  Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[66]  M. Uhlén,et al.  A novel affinity gene fusion system allowing protein A-based recovery of non-immunoglobulin gene products. , 2002, Journal of biotechnology.

[67]  L. Abrahmsén,et al.  Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy , 2007, Expert opinion on biological therapy.

[68]  H. Berglund,et al.  An affibody in complex with a target protein: Structure and coupled folding , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[69]  S. Hober,et al.  Affibody-mediated transferrin depletion for proteomics applications. , 2007, Biotechnology journal.

[70]  V. Tolmachev,et al.  Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. , 2007, Current opinion in drug discovery & development.

[71]  C. Barbas,et al.  Phage display of combinatorial antibody libraries. , 1997, Current opinion in biotechnology.

[72]  John Löfblom,et al.  A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry. , 2008, Protein engineering, design & selection : PEDS.

[73]  J. Wells,et al.  Hormone phage: An enrichment method for variant proteins with altered binding properties , 1990, Proteins.

[74]  Matthias Paschke,et al.  Phage display systems and their applications , 2006, Applied Microbiology and Biotechnology.

[75]  E. Johansson,et al.  Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. , 2008, Journal of molecular biology.

[76]  Motomu Shimaoka,et al.  Directed evolution to probe protein allostery and integrin I domains of 200,000-fold higher affinity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[77]  G. Winter,et al.  Phage antibodies: filamentous phage displaying antibody variable domains , 1990, Nature.

[78]  V. Streltsov,et al.  Structure of a shark IgNAR antibody variable domain and modeling of an early‐developmental isotype , 2005, Protein science : a publication of the Protein Society.

[79]  H. Binz,et al.  DARPins: a new generation of protein therapeutics. , 2008, Drug discovery today.

[80]  G. Adams,et al.  Selection and characterization of HER2/neu-binding affibody ligands. , 2004, Protein engineering, design & selection : PEDS.

[81]  N. Habib,et al.  Adenovirus 5 vector genetically re-targeted by an Affibody molecule with specificity for tumor antigen HER2/neu , 2007, Cancer Gene Therapy.

[82]  H. de Haard,et al.  Properties, production, and applications of camelid single-domain antibody fragments , 2007, Applied Microbiology and Biotechnology.

[83]  S. Koide,et al.  Phage display for engineering and analyzing protein interaction interfaces. , 2007, Current opinion in structural biology.

[84]  P. Daugherty Protein engineering with bacterial display. , 2007, Current opinion in structural biology.

[85]  R. Pehrson,et al.  Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. , 2007, Cancer research.

[86]  George Georgiou,et al.  Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[87]  A. Plückthun,et al.  Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries. , 2006, Protein engineering, design & selection : PEDS.

[88]  Jinha M. Park,et al.  Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. , 2004, Protein engineering, design & selection : PEDS.

[89]  Andreas Plückthun,et al.  Allosteric inhibition of aminoglycoside phosphotransferase by a designed ankyrin repeat protein. , 2005, Structure.

[90]  M. Uhlén,et al.  All individual domains of staphylococcal protein A show Fab binding. , 2006, FEMS immunology and medical microbiology.

[91]  A. Koide,et al.  The fibronectin type III domain as a scaffold for novel binding proteins. , 1998, Journal of molecular biology.

[92]  L. James,et al.  Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold. , 2004, Journal of molecular biology.

[93]  H. Brumer,et al.  Chemical Synthesis of Triple‐Labelled Three‐Helix Bundle Binding Proteins for Specific Fluorescent Detection of Unlabelled Protein , 2005, Chembiochem : a European journal of chemical biology.

[94]  T. Härd,et al.  Stabilization of a β-hairpin in monomeric Alzheimer's amyloid-β peptide inhibits amyloid formation , 2008, Proceedings of the National Academy of Sciences.

[95]  A. Plückthun,et al.  In vitro selection and evolution of functional proteins by using ribosome display. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[96]  M. Uhlén,et al.  Construction and characterization of affibody-Fc chimeras produced in Escherichia coli. , 2002, Journal of immunological methods.

[97]  A. Skerra,et al.  A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin. , 2000, Journal of molecular biology.

[98]  A. Plückthun,et al.  High-affinity binders selected from designed ankyrin repeat protein libraries , 2004, Nature Biotechnology.

[99]  A. Karlström,et al.  Affibody protein capture microarrays: synthesis and evaluation of random and directed immobilization of affibody molecules. , 2005, Analytical biochemistry.

[100]  P. Nygren,et al.  Binding proteins from alternative scaffolds. , 2004, Journal of immunological methods.

[101]  George Georgiou,et al.  Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli , 2007, Nature Biotechnology.

[102]  James Inglese,et al.  Directed evolution of PDZ variants to generate high-affinity detection reagents. , 2005, Protein engineering, design & selection : PEDS.

[103]  P. Nygren,et al.  Alternative binding proteins: Affibody binding proteins developed from a small three‐helix bundle scaffold , 2008, The FEBS journal.

[104]  E. Lundberg,et al.  Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. , 2007, Journal of immunological methods.

[105]  S. Sidhu Phage display in pharmaceutical biotechnology. , 2000, Current opinion in biotechnology.

[106]  R. Barrett,et al.  Peptides on phage: a vast library of peptides for identifying ligands. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[107]  S. Lindström,et al.  Selection and characterization of Affibody ligands binding to Alzheimer amyloid β peptides , 2007 .

[108]  W. Dower,et al.  An in vitro polysome display system for identifying ligands from very large peptide libraries. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[109]  W. Stemmer,et al.  Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains , 2005, Nature biotechnology.

[110]  C. Barbas,et al.  Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[111]  C. Borrebaeck,et al.  Antibodies in diagnostics - from immunoassays to protein chips. , 2000, Immunology today.

[112]  C. Barbas,et al.  Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[113]  Lucy J. Holt,et al.  Domain antibodies: proteins for therapy. , 2003, Trends in biotechnology.

[114]  M. Uhlén,et al.  Human immunoglobulin A (IgA)-specific ligands from combinatorial engineering of protein A. , 2002, European journal of biochemistry.

[115]  W. Arap,et al.  Display technologies: Application for the discovery of drug and gene delivery agents , 2006, Advanced Drug Delivery Reviews.

[116]  M. Uhlén,et al.  Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain , 1997, Nature Biotechnology.

[117]  M. Uhlén,et al.  Ligands selected from combinatorial libraries of protein A for use in affinity capture of apolipoprotein A-1M and taq DNA polymerase. , 2000, Journal of biotechnology.

[118]  J. Carlsson,et al.  Tumor imaging using a picomolar affinity HER2 binding affibody molecule. , 2006, Cancer research.

[119]  M. Michel-beyerle,et al.  Ultrafast electron transfer in the complex between fluorescein and a cognate engineered lipocalin protein, a so-called anticalin. , 2002, Biochemistry.

[120]  M. Uhlén,et al.  A combinatorial library of an α-helical bacterial receptor domain , 1995 .

[121]  Xianghua Yan,et al.  Ribosome-display technology: applications for directed evolution of functional proteins. , 2006, Drug discovery today.

[122]  K D Wittrup,et al.  Yeast surface display for directed evolution of protein expression, affinity, and stability. , 2000, Methods in enzymology.

[123]  E. Lundberg,et al.  Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule. , 2008, Journal of immunological methods.

[124]  J. Devlin,et al.  Random peptide libraries: a source of specific protein binding molecules. , 1990, Science.

[125]  Vladimir Tolmachev,et al.  111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[126]  G. Georgiou,et al.  Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[127]  S. Ståhl,et al.  Re-targeted adenovirus vectors with dual specificity; binding specificities conferred by two different Affibody molecules in the fiber , 2009, Gene Therapy.

[128]  Andreas Plückthun,et al.  In-vitro protein evolution by ribosome display and mRNA display. , 2004, Journal of immunological methods.

[129]  Y. Husimi,et al.  An in vitro DNA virus for in vitro protein evolution , 2001, FEBS letters.

[130]  K Dane Wittrup,et al.  Yeast surface display for protein engineering and characterization , 2007, Current Opinion in Structural Biology.

[131]  Andreas Plückthun,et al.  Direct selection of antibodies from complex libraries with the protein fragment complementation assay. , 2006, Journal of molecular biology.

[132]  M. Uhlén,et al.  Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling. , 1999, Protein engineering.

[133]  R. Hoess,et al.  Protein design and phage display. , 2001, Chemical reviews.

[134]  Carlos F. Barbas,et al.  Phage display: a Laboratory manual , 2014 .

[135]  A. P. Chapman,et al.  PEGylated antibodies and antibody fragments for improved therapy: a review. , 2002, Advanced drug delivery reviews.

[136]  A. Mire-Sluis,et al.  Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction. , 2002, Current pharmaceutical biotechnology.

[137]  Caroline Kampf,et al.  Affibody-beta-galactosidase immunoconjugates produced as soluble fusion proteins in the Escherichia coli cytosol. , 2003, Journal of immunological methods.

[138]  T Prospero,et al.  "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[139]  Dario Neri,et al.  Selection of single domain binding proteins by covalent DNA display. , 2007, Protein engineering, design & selection : PEDS.

[140]  G. Georgiou,et al.  Antibody affinity maturation using bacterial surface display. , 1998, Protein engineering.

[141]  M. Geiser,et al.  Evaluation of antibodies fused to minor coat protein III and major coat protein VIII of bacteriophage M13. , 1995, Gene.

[142]  M. Uhlén,et al.  Affibody molecules in protein capture microarrays: evaluation of multidomain ligands and different detection formats. , 2007, Journal of proteome research.

[143]  C. Briand,et al.  Drug Export Pathway of Multidrug Exporter AcrB Revealed by DARPin Inhibitors , 2006, PLoS biology.

[144]  M. Vogel,et al.  Designed Ankyrin Repeat Proteins as Anti‐Idiotypic‐Binding Molecules , 2007, Annals of the New York Academy of Sciences.

[145]  L E Williams,et al.  Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. , 1996, Cancer research.

[146]  Gary Walsh,et al.  Biopharmaceuticals: recent approvals and likely directions. , 2005, Trends in biotechnology.

[147]  R. Rudolph,et al.  Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. , 2005, Trends in biotechnology.

[148]  Fine affinity discrimination by normalized fluorescence activated cell sorting in staphylococcal surface display. , 2005, FEMS microbiology letters.

[149]  R. Cortese,et al.  Efficient display of an HCV cDNA expression library as C-terminal fusion to the capsid protein D of bacteriophage lambda. , 1998, Journal of molecular biology.

[150]  A. Skerra Alternative non-antibody scaffolds for molecular recognition. , 2007, Current opinion in biotechnology.

[151]  Lin Sun,et al.  Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. , 2006, Chemistry & biology.

[152]  K Dane Wittrup,et al.  Isolating and engineering human antibodies using yeast surface display , 2006, Nature Protocols.

[153]  Andreas Plückthun,et al.  Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target , 2007, Nature Methods.

[154]  B. Power,et al.  A new generation of protein display scaffolds for molecular recognition , 2006, Protein science : a publication of the Protein Society.

[155]  G. P. Smith,et al.  Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. , 1985, Science.

[156]  P. Diot,et al.  EPI-hNE4, a Proteolysis-Resistant Inhibitor of Human Neutrophil Elastase and Potential Anti-Inflammatory Drug for Treating Cystic Fibrosis , 2006, Journal of Pharmacology and Experimental Therapeutics.

[157]  A. Plückthun,et al.  Engineering novel binding proteins from nonimmunoglobulin domains , 2005, Nature Biotechnology.

[158]  M. Uhlén,et al.  An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein. , 1999, Immunotechnology : an international journal of immunological engineering.

[159]  Y. Cho,et al.  Mining a yeast library for brain endothelial cell-binding antibodies , 2007, Nature Methods.

[160]  R. Roberts Totally in vitro protein selection using mRNA-protein fusions and ribosome display. , 1999, Current opinion in chemical biology.

[161]  J W Szostak,et al.  RNA-peptide fusions for the in vitro selection of peptides and proteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[162]  Andreas Plückthun,et al.  A designed ankyrin repeat protein evolved to picomolar affinity to Her2. , 2007, Journal of molecular biology.

[163]  M. Uhlén,et al.  Epitope mapping of antibodies using bacterial surface display , 2008, Nature Methods.

[164]  Jenny Rönnmark,et al.  Inclusion of a non-immunoglobulin binding protein in two-site ELISA for quantification of human serum proteins without interference by heterophilic serum antibodies. , 2003, Journal of immunological methods.